{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T13:01:05Z","timestamp":1778072465496,"version":"3.51.4"},"reference-count":24,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2024,10,1]]},"abstract":"<jats:sec id=\"ab-eoi240052-4\"><jats:title>Importance<\/jats:title><jats:p>If preperimetric glaucoma reduces patient-reported vision-related quality of life (VRQoL), clinicians might consider earlier and more aggressive treatment of some patients with ocular hypertension and early glaucoma.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi240052-5\"><jats:title>Objective<\/jats:title><jats:p>To determine the impact of preperimetric glaucoma and early glaucomatous visual field (VF) loss on participants\u2019 VRQoL compared with participants who did not develop glaucoma in the Ocular Hypertension Treatment Study (OHTS).<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi240052-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This cross-sectional study used data from participants enrolled in the OHTS from 1994 to 1996 who completed 20-year examination follow-up and VRQoL surveys from January 7, 2016, to November 19, 2019. Diagnosis of primary open-angle glaucoma (POAG) required reproducible changes in VFs or optic discs as determined by reading centers and attributed to glaucoma by a masked end point committee. Data analysis was performed from June 27, 2023 to March 7, 2024.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi240052-7\"><jats:title>Exposure<\/jats:title><jats:p>Ocular hypertension and glaucoma.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi240052-8\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>Cross-sectional analysis of Rasch-calibrated total scores of the National Eye Institute Visual Function Questionnaire (VFQ) and the Glaucoma Quality of Life (GQL) survey was performed. Total scores were standardized from 0 (poor) to 100 (good). The main outcomes were differences in total VRQoL scores between participants who did not develop POAG (control) and 4 mutually exclusive POAG groups: unilateral or bilateral disc POAG with no glaucomatous VF loss in either eye and unilateral or bilateral VF POAG with or without disc changes. Differences in total VRQoL scores were analyzed using univariate and multivariate linear regression models.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi240052-9\"><jats:title>Results<\/jats:title><jats:p>Of 1636 participants originally enrolled in the OHTS, 679 (42%) completed the 20-year examination and VRQoL surveys. Of those participants completing 20-year follow-up, mean (SD) participant age at follow-up was 73.8 (7.7) years, and 412 of 679 participants (60.7%) self-reported as female. The mean (SD) Rasch-calibrated total VFQ scores were 72.5 (13.4) in the no POAG group (control) vs 72.7 (13.8) in the unilateral disc POAG group (difference, 0.17; 95% CI, \u22123.17 to 3.41; <jats:italic>P<\/jats:italic>\u2009=\u2009.92), 73.4 (14.0) in the bilateral disc POAG group (difference, 0.92; 95% CI, \u22122.93 to 4.77; <jats:italic>P<\/jats:italic>\u2009=\u2009.64), 69.2 (14.5) in the unilateral VF POAG group (difference, 3.33; 95% CI, \u22126.38 to \u22120.27; <jats:italic>P<\/jats:italic>\u2009=\u2009.03), and 58.5 (16.9) in the bilateral VF POAG group (difference, \u221213.96; 95% CI, \u221217.73 to \u221210.19; <jats:italic>P<\/jats:italic>&amp;amp;lt;.001). Similar results were found for the GQL questionnaire.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi240052-10\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>In this cross-sectional study, among the surviving participants of OHTS who completed the 20-year follow-up examination, those participants who developed preperimetric POAG but no glaucomatous VF loss did not report lower VFQoL compared with participants who did not develop POAG. This finding should allow clinicians and patients the time to determine the frequency of examinations and whether the initiation of treatment is appropriate.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaophthalmol.2024.3282","type":"journal-article","created":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T15:46:10Z","timestamp":1724946370000},"page":"935","source":"Crossref","is-referenced-by-count":3,"title":["Quality of Life and Primary Open-Angle Glaucoma in the Ocular Hypertension Treatment Study"],"prefix":"10.1001","volume":"142","author":[{"given":"Mae O.","family":"Gordon","sequence":"first","affiliation":[{"name":"Washington University School of Medicine in St Louis, Missouri"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Gao","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine in St Louis, Missouri"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Burkland","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine in St Louis, Missouri"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia B.","family":"Huecker","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine in St Louis, Missouri"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart K.","family":"Gardiner","sequence":"additional","affiliation":[{"name":"Legacy Devers Eye Institute, Portland, Oregon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pradeep","family":"Ramulu","sequence":"additional","affiliation":[{"name":"Johns Hopkins University, Baltimore, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda M.","family":"Zangwill","sequence":"additional","affiliation":[{"name":"University of California, San Diego, La Jolla, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dale K.","family":"Heuer","sequence":"additional","affiliation":[{"name":"Medical College of Wisconsin, Milwaukee"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eve J.","family":"Higginbotham","sequence":"additional","affiliation":[{"name":"University of Pennsylvania, Philadelphia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard K.","family":"Parrish","sequence":"additional","affiliation":[{"name":"University of Miami, Miami, Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"Kass","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine in St Louis, Missouri"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"4","key":"eoi240052r1","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1001\/jamaophthalmol.2013.2602","article-title":"Association between rates of binocular visual field loss and vision-related quality of life in patients with glaucoma.","volume":"131","author":"Lisboa","year":"2013","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"eoi240052r2","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1001\/jamaophthalmol.2014.5319","article-title":"Association between progressive retinal nerve fiber layer loss and longitudinal change in quality of life in glaucoma.","volume":"133","author":"Gracitelli","year":"2015","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"eoi240052r3","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.ophtha.2014.08.014","article-title":"Longitudinal changes in quality of life and rates of progressive visual field loss in glaucoma patients.","volume":"122","author":"Medeiros","year":"2015","journal-title":"Ophthalmology"},{"issue":"1","key":"eoi240052r4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ophtha.2017.08.034","article-title":"Predicting vision-related disability in glaucoma.","volume":"125","author":"Abe","year":"2018","journal-title":"Ophthalmology"},{"issue":"7","key":"eoi240052r5","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1136\/bjophthalmol-2018-312357","article-title":"Is vision-related quality of life impaired in patients with preperimetric glaucoma?","volume":"103","author":"Daga","year":"2019","journal-title":"Br J Ophthalmol"},{"key":"eoi240052r6","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ajo.2022.12.018","article-title":"Vision-related quality of life among healthy, preperimetric glaucoma, and perimetric glaucoma patients.","volume":"248","author":"Nishida","year":"2023","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"eoi240052r7","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1001\/archopht.1997.01100150779014","article-title":"Influence of glaucomatous visual field loss on health-related quality of life.","volume":"115","author":"Gutierrez","year":"1997","journal-title":"Arch Ophthalmol"},{"issue":"9","key":"eoi240052r8","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/j.ophtha.2005.03.028","article-title":"Treatment and vision-related quality of life in the early manifest glaucoma trial.","volume":"112","author":"Hyman","year":"2005","journal-title":"Ophthalmology"},{"issue":"2","key":"eoi240052r9","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1097\/00061198-200204000-00012","article-title":"Glaucoma patients\u2019 assessment of their visual function and quality of life.","volume":"11","author":"Jampel","year":"2002","journal-title":"J Glaucoma"},{"issue":"8","key":"eoi240052r10","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1111\/aos.12839","article-title":"Visual impairment and vision-related quality of life in the Early Manifest Glaucoma Trial after 20 years of follow-up.","volume":"93","author":"Peters","year":"2015","journal-title":"Acta Ophthalmol"},{"issue":"8","key":"eoi240052r11","doi-asserted-by":"publisher","first-page":"W163","DOI":"10.7326\/0003-4819-147-8-200710160-00010-w1","article-title":"Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration.","volume":"147","author":"Vandenbroucke","year":"2007","journal-title":"Ann Intern Med"},{"issue":"5","key":"eoi240052r12","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1001\/archopht.117.5.573","article-title":"The Ocular Hypertension Treatment Study: design and baseline description of the participants.","volume":"117","author":"Gordon","year":"1999","journal-title":"Arch Ophthalmol"},{"issue":"6","key":"eoi240052r13","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1001\/archopht.120.6.701","article-title":"The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma.","volume":"120","author":"Kass","year":"2002","journal-title":"Arch Ophthalmol"},{"issue":"5","key":"eoi240052r14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamaophthalmol.2021.0341","article-title":"Assessment of cumulative incidence and severity of primary open-angle glaucoma among participants in the Ocular Hypertension Treatment Study after 20 years of follow-up.","volume":"139","author":"Kass","year":"2021","journal-title":"JAMA Ophthalmol"},{"issue":"5","key":"eoi240052r15","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1136\/bjo.83.5.546","article-title":"Patients\u2019 perception of visual impairment in glaucoma: a pilot study.","volume":"83","author":"Nelson","year":"1999","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"eoi240052r16","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/00061198-200304000-00009","article-title":"Quality of life in glaucoma and its relationship with visual function.","volume":"12","author":"Nelson","year":"2003","journal-title":"J Glaucoma"},{"issue":"5","key":"eoi240052r17","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1586\/erp.11.59","article-title":"Rating scales and Rasch measurement.","volume":"11","author":"Andrich","year":"2011","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"3","key":"eoi240052r18","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1007\/s00417-004-0984-x","article-title":"Integrated visual fields: a new approach to measuring the binocular field of view and visual disability.","volume":"243","author":"Crabb","year":"2005","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"6","key":"eoi240052r19","doi-asserted-by":"publisher","first-page":"2878","DOI":"10.1167\/iovs.09-4494","article-title":"The psychometric validity of the NEI VFQ-25 for use in a low-vision population.","volume":"51","author":"Marella","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"11","key":"eoi240052r20","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1001\/archopht.1997.01100160617016","article-title":"Visual function and quality of life among patients with glaucoma.","volume":"115","author":"Parrish","year":"1997","journal-title":"Arch Ophthalmol"},{"issue":"5","key":"eoi240052r21","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/S0161-6420(00)00624-2","article-title":"Quality of life in newly diagnosed glaucoma patients: The Collaborative Initial Glaucoma Treatment Study.","volume":"108","author":"Janz","year":"2001","journal-title":"Ophthalmology"},{"issue":"14","key":"eoi240052r22","doi-asserted-by":"publisher","first-page":"4556","DOI":"10.1167\/iovs.19-28023","article-title":"Vision parameters most important to functionality in glaucoma.","volume":"60","author":"Shakarchi","year":"2019","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"eoi240052r23","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1001\/jamaophthalmol.2014.4908","article-title":"Patient-reported vision-related quality of life differences between superior and inferior hemifield visual field defects in primary open-angle glaucoma.","volume":"133","author":"Cheng","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"eoi240052r24","volume-title":"Clinical Decisions in Glaucoma","author":"Hodapp","year":"1993"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2822888\/jamaophthalmology_gordon_2024_oi_240052_1727818420.51573.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T15:15:57Z","timestamp":1729178157000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2822888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,1]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2024.3282","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,1]]}}}